Literature DB >> 7884870

Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.

G Roderiquez1, T Oravecz, M Yanagishita, D C Bou-Habib, H Mostowski, M A Norcross.   

Abstract

The mechanism of heparan sulfate (HS)-mediated human immunodeficiency virus type 1 (HIV-1) binding to and infection of T cells was investigated with a clone (H9h) of the T-cell line H9 selected on the basis of its high level of cell surface CD4 expression. Semiquantitative PCR analysis revealed that enzymatic removal of cell surface HS by heparitinase resulted in a reduction of the amount of HIV-1 DNA present in H9h cells 4 h after exposure to virus. Assays of the binding of recombinant envelope proteins to H9h cells demonstrated a structural requirement for an oligomeric form of gp120/gp41 for HS-dependent binding to the cell surface. The ability of the HIV-1 envelope to bind simultaneously to HS and CD4 was shown by immunoprecipitation of HS with either antienvelope or anti-CD4 antibodies from 35SO4(2-)-labeled H9h cells that had been incubated with soluble gp140. Soluble HS blocked the binding of monoclonal antibodies that recognize the V3 and C4 domains of the envelope protein to the surface of H9 cells chronically infected with HIV-1IIIB. The V3 domain was shown to be the major site of envelope-HS interaction by examining the effects of both antienvelope monoclonal antibodies and heparitinase on the binding of soluble gp140 to H9h cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884870      PMCID: PMC188892     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells.

Authors:  C Y Ou; S Kwok; S W Mitchell; D H Mack; J J Sninsky; J W Krebs; P Feorino; D Warfield; G Schochetman
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

4.  CD4-independent infection of human neural cells by human immunodeficiency virus type 1.

Authors:  J M Harouse; C Kunsch; H T Hartle; M A Laughlin; J A Hoxie; B Wigdahl; F Gonzalez-Scarano
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

5.  Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection.

Authors:  T Hattori; A Koito; K Takatsuki; H Kido; N Katunuma
Journal:  FEBS Lett       Date:  1989-05-08       Impact factor: 4.124

6.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Generation of human monoclonal antibodies to human immunodeficiency virus.

Authors:  M K Gorny; V Gianakakos; S Sharpe; S Zolla-Pazner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies.

Authors:  M R Posner; H Elboim; D Santos
Journal:  Hybridoma       Date:  1987-12

9.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

10.  Neutralizing monoclonal antibodies to the AIDS virus.

Authors:  E K Thomas; J N Weber; J McClure; P R Clapham; M C Singhal; M K Shriver; R A Weiss
Journal:  AIDS       Date:  1988-02       Impact factor: 4.177

View more
  79 in total

1.  The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface.

Authors:  J Cladera; I Martin; P O'Shea
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

Review 2.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

3.  GapA and CrmA coexpression is essential for Mycoplasma gallisepticum cytadherence and virulence.

Authors:  L Papazisi; S Frasca; M Gladd; X Liao; D Yogev; S J Geary
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Depressed neurofilament expression associates with apolipoprotein E3/E4 genotype in maturing human fetal neurons exposed to HIV-1.

Authors:  Ricardo Martinez; Wu Chunjing; Rebeca Geffin; Micheline McCarthy
Journal:  J Neurovirol       Date:  2012-08       Impact factor: 2.643

Review 5.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

6.  Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells.

Authors:  A Valenzuela; J Blanco; B Krust; R Franco; A G Hovanessian
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Authors:  Chee Wah Tan; Chit Laa Poh; I-Ching Sam; Yoke Fun Chan
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Identification of cell surface molecules that interact with pseudorabies virus.

Authors:  A Karger; T C Mettenleiter
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.